about
Improving the clinical impact of biomaterials in cancer immunotherapy.Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesWhole Tumor Antigen Vaccines: Where Are We?CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseasesUsing magnetic resonance imaging to evaluate dendritic cell-based vaccinationDendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeCancer immunotherapy comes of ageImmunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner.Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.Whole tumor antigen vaccines.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Increasing the efficacy of tumor cell vaccines by enhancing cross primingTumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.Overview of cancer vaccines: considerations for development.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicityA Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Immune-checkpoint blockade and active immunotherapy for glioma.Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Serum autoantibodies as biomarkers for early cancer detection.Tumor lysate-loaded biodegradable microparticles as cancer vaccines.Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Melanoma vaccines: developments over the past 10 years.Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.Deciphering and reversing tumor immune suppression.Update on vaccines for high-risk melanoma.Applying biodegradable particles to enhance cancer vaccine efficacy.Potential approaches for more successful dendritic cell-based immunotherapy.
P2860
Q26766267-5734683A-82BB-4220-AFEC-F1EBED036DD6Q26772715-2F7F38FA-A691-4ADE-BC1A-511B995BAC24Q26783866-76C1FC5F-B4ED-4C83-AAD3-0F14BB09EC97Q26999045-45BC44EC-06A4-45A7-800A-6C8B684B787BQ27316977-142C2D3C-D630-4F21-B96C-9F255F922666Q28087485-E54B0C5C-2D9D-459A-9689-041D991F001BQ29619918-1D8D8CA7-D6FE-4BCE-AAED-940B90F40F88Q33576327-68F0580F-16C2-4773-B967-28FBC6166CC1Q33691858-CF290F8C-E838-4974-858B-B2B5657E6521Q33724878-E27CD09D-CDC8-4CD7-BB36-08693E21144AQ34049184-97C3107F-1199-4037-8CBC-3D8A16A86A9FQ34110309-B97C6066-65B3-4615-97C7-26473BA2FCE8Q34292741-B6C936F5-616F-4B73-B950-E67CBB9522D7Q34551535-FB6D4EEB-61AA-457F-9710-100E25C4C476Q34634220-67978EFE-242B-44B1-8945-CF0E3D25B833Q35058235-B3D210AD-8832-4CA2-B062-C121D888191DQ35063621-011E8665-2B0B-497E-9686-D67406DB17BAQ35318315-4115E4E3-28FB-4DE2-A3A6-323F4E2C0955Q35799695-6457A90D-35C0-439A-B569-76859EA51725Q35900294-D9573667-1A97-49C9-9A60-D38368E09DFEQ35939427-CEA9D477-CF09-4F55-AD56-1F481B059E1FQ36288105-B6ECCB53-9D71-477C-B557-931B32F0049AQ36391595-A2B5BCB8-997C-4566-AA9D-920D66868E5DQ36631339-429F5CE1-6863-4108-8F69-B3DF76E62028Q36643661-8B2B399D-4C2D-41A5-BAAE-16AC4A7C56CCQ36710917-56EBAE22-F864-45B8-B1EF-D55520ADA862Q36847343-C4DD929C-2855-4F54-B8A0-B8368E2AA7C4Q36958112-75EBC1E9-B4DD-4746-A648-92A15C5C60A9Q37420586-ED589D1D-27E0-4D39-AA51-8B97F057CBD5Q37542092-03CDFC4A-0F09-4127-984E-712854960FC6Q37622471-1727CD2A-9BAC-46A3-A60B-61D493D4EE2CQ37670779-B63F3094-642A-495C-8F3E-493B20412000Q37854072-2F2E4C76-CD72-475C-A257-EBFC02442112Q37873932-D3CDD33E-40B3-4867-B222-337D8E9AC418Q37892595-1C1560F1-9C2E-48F9-A93B-17E56D480082Q38056365-C35EB28F-AD7C-4976-96DD-73F1C7D71D39Q38124437-780E20B5-9EF7-462D-9F8A-5B89B2516B18Q38208715-4F414813-DAF8-498C-B2A1-B67B34538CC1Q38212549-9B66D276-45AF-4181-9C70-99B535C07E40Q38305650-D7280C0F-1373-44D6-A021-349B4488BA42
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antigens for cancer immunotherapy.
@en
Antigens for cancer immunotherapy.
@nl
type
label
Antigens for cancer immunotherapy.
@en
Antigens for cancer immunotherapy.
@nl
prefLabel
Antigens for cancer immunotherapy.
@en
Antigens for cancer immunotherapy.
@nl
P2093
P50
P1476
Antigens for cancer immunotherapy
@en
P2093
Christopher W Schmidt
J Alejandro López
Michelle A Neller
P304
P356
10.1016/J.SMIM.2008.09.006
P577
2008-10-23T00:00:00Z